DPP4 and pancreatitis: Future studies should evaluate other patient important outcomes, including the safety of these therapies in people with type 3c diabetes, and address concerns surrounding drug‐specific side effects, for example the risk of hypoglycaemia with sulphonylureas,15 and the potential association of DPP4‐inhibitors and increased risk of pancreatitis.12